ID: ALA4791373

Max Phase: Preclinical

Molecular Formula: C22H26N8O6S

Molecular Weight: 530.57

Molecule Type: Unknown

Representations

Canonical SMILES:  Nc1ncnc2c1ncn2[C@@H]1O[C@H](CSCCNC(=O)C2Cc3ccc([N+](=O)[O-])cc3CN2)[C@@H](O)[C@H]1O

Standard InChI:  InChI=1S/C22H26N8O6S/c23-19-16-20(27-9-26-19)29(10-28-16)22-18(32)17(31)15(36-22)8-37-4-3-24-21(33)14-6-11-1-2-13(30(34)35)5-12(11)7-25-14/h1-2,5,9-10,14-15,17-18,22,25,31-32H,3-4,6-8H2,(H,24,33)(H2,23,26,27)/t14?,15-,17-,18-,22-/m1/s1

Standard InChI Key:  DFGPQNLIEOZNQC-PEVIPMCXSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 530.57

Molecular Weight (Monoisotopic): 530.1696

AlogP: -0.50

#Rotatable Bonds: 8

Polar Surface Area: 203.58

Molecular Species: NEUTRAL

HBA: 13

HBD: 5

#RO5 Violations: 2

HBA (Lipinski): 14

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 3

CX Acidic pKa: 12.47

CX Basic pKa: 7.08

CX LogP: -0.42

CX LogD: -0.59

Aromatic Rings: 3

Heavy Atoms: 37

QED Weighted: 0.14

Np Likeness Score: -0.13

References

1. Lu J,Bart AG,Wu Q,Criscione KR,McLeish MJ,Scott EE,Grunewald GL.  (2020)  Structure-Based Drug Design of Bisubstrate Inhibitors of Phenylethanolamine N-Methyltransferase Possessing Low Nanomolar Affinity at Both Substrate Binding Domains.,  63  (22): [PMID:33147410] [10.1021/acs.jmedchem.0c01475]

Source

Source(1):

• Scientific Literature